Penn Pharma chief operating officer Mark Dean-Netscher said, “With a background £18 million expansion program and significant construction activity on site, this is a fantastic achievement on our continued journey for Operational Excellence in Penn. We have superb engagement from all of our staff with a very active ‘near miss’ system and safety-focused culture in place. Our safety record ranks with the best in the pharmaceutical sector. It shows that Penn applies the same importance to the safety of our staff, as we do to the safety of the medicines we supply to patients worldwide.”
Penn Pharma provides integrated drug development, clinical trial supply and manufacturing services to the international healthcare industry. The company recently retained its accreditation for ISO14001 standard for environmental management, following a two-day audit by its certification body.